ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention - Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)
"Percutaneous coronary intervention (PCI) with stent implantation has become the first choice of treatment for acute myocardial infarction . The most often used metals and metallic alloys for manufacturing stents have a net positive electrical charge on their surface . "
"For these reasons, in the setting of LT candidates, perhaps bare metal stents are the ideal, as dual antiplatelet therapy should be administered for a shorter period of time than with drug-eluting stents. Normally, although a minimum of 1 month of dual antiplatelet therapy is recommended for bare stents, only 2 weeks of clopidogrel can be given if there is a significant increase in the risk of bleeding . Finally, surgical revascularization has a very high morbidity and mortality in patients with cirrhosis     , although some successful cases have been reported . "
[Show abstract][Hide abstract] ABSTRACT: The heart and liver are organs that are closely related in both health and disease. Patients who undergo liver transplantation may suffer from heart disease that is: (a) related to the original cause of the liver disease such as hemochromatosis, (b) related to the liver disease itself, or (c) related to other associated conditions. Furthermore, liver transplantation is one of the most cardiovascular stressful events that a patient with cirrhosis may undergo. After liver transplantation, the progression of pre-existing or the development of new-onset cardiac disease may occur. This article reviews the relationship between the heart and liver transplantation in the pre-transplant, intra-operative, and post-transplant periods.
Journal of Hepatology 11/2010; 54(4):810-22. DOI:10.1016/j.jhep.2010.11.003 · 10.40 Impact Factor
"Dual antiplatelet therapy is required for a longer period after the implantation of drug-eluting stents. The ACC/AHA/SCAI guidelines recommend that dual antiplatelet therapy be continued for 1 year after implantation of drugeluting stents in patients who are not at high risk for bleeding (and, at minimum, 3 months for sirolimus-eluting stents, and 6 months for paclitaxel-eluting stents) . In studies examining stent thrombosis, the most powerfu predictor of this often-catastrophic event is the discontinuation of antiplatelet therapy. "
[Show abstract][Hide abstract] ABSTRACT: Given the increasing complexity of hospitalized patients and the increasing specialization among surgeons, there is greater reliance on hospitalists for preoperative assessment. Several institutions have developed surgery/medicine comanagement teams that jointly care for patients in the perioperative setting. Despite a growing body of evidence, it is important to recognize there are many gaps in the perioperative literature. This has led to considerable dependence on consensus statements and expert opinion when evaluating patients perioperatively. This review focuses on the preoperative cardiovascular and pulmonary evaluation of the hospitalized patient: the two systems responsible for the greatest morbidity and mortality. Prevention of postoperative venous thromboembolism and management of perioperative hyperglycemia are also discussed.
Medical Clinics of North America 04/2008; 92(2):325-48, viii. DOI:10.1016/j.mcna.2007.10.003 · 2.80 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.